Patent ID: 8945564
Filing Date: 2015-02-03
Classification: A61P,C07K

Abstract:
1. A stable liquid pharmaceutical composition comprising: a) an antagonist anti-CD40 monoclonal antibody as a therapeutically or prophylactically active component, wherein said monoclonal antibody is capable of specifically binding to a human CD40 antigen expressed on the surface of a human B cell, said monoclonal antibody being free of significant agonist activity when bound to the CD40 antigen expressed on the surface of said B cell; b) an amount of an isotonizing agent sufficient to render said composition as having an osmolality of about 240 mmol/kg to about 360 mmol/kg, wherein said isotonizing agent is arginine in its acidic form (arginine-HCl), and wherein said composition does not include NaCl as an additional isotonizing agent; and c) a buffering agent to maintain the pH of said composition within a range from about pH 5.0 to about pH 7.0, wherein said buffering agent is a citrate/citric acid buffer; wherein said antagonist anti-CD40 monoclonal antibody is present in said composition at a concentration of about 0.1 mg/ml to about 50.0 mg/ml and is selected from the group consisting of: wherein the concentration of said buffering agent is about 5 mM to about 100 mM, and wherein said composition comprises arginine-HCl at a concentration of about 50 mM to about 200 mM.